Ryan Drant

Ryan joined NEA in 1996, and became a General Partner in 2004. He specializes in healthcare investments in the specialty pharma, medical device and healthcare information technology sectors. Present board memberships include BENU, Carticept Medical, Concentric Medical, ExploraMed III, ForHealth Technologies, Intrinsic Therapeutics, Neotract, PatientKeeper, Simplex Diabetic Supply, Spine Wave, Viacor and Vibrynt. Ryan also co-manages NEA's investment in TriVascular2. Past board memberships include ESP Pharma (acquired by Protein Design Labs, Inc.), Esprit Pharma (acquired by Allergan), FoxHollow Technologies (NASDAQ: FOXH), Provation Medical (acquired by Wolters Kluwer), and Proxima Therapeutics (acquired by Cytyc Corporation), and Ryan co-led NEA’s investment in Xcel Pharmaceuticals (acquired by Valeant Pharmaceuticals, Inc.). Prior to joining NEA, Ryan was with the Health Care Investment Banking Group of Alex. Brown & Sons in San Francisco. Previously, he worked in the San Francisco office of Arthur Andersen & Co. Ryan received a BA from Stanford University.